Scarce information is available on the use of ponatinib as second-line treatment in chronic phase chronic myeloid leukemia (CP-CML) patients resistant and/or intolerant to prior tyrosine kinase inhibitor (TKI) therapy. We collected data from 29 CML patients, with a median age of 54 years (range 32-72). Eleven patients had received dasatinib, 15 patients received nilotinib, and 3 patients received imatinib as first-line treatment. Forty-five percent of patients started ponatinib for secondary resistance, 38% for primary resistance, 7% for severe intolerance associated to a molecular warning, 7% due to the presence of a T315I mutation, and 3% for severe intolerance. Ponatinib was started at a dose of 45 mg in 60% of patients, 30 mg in 38%, and 15 mg in 2% of patients. Overall, at a median follow-up of 12 months, 85% of treated patients improved the level of response as compared to baseline, with 10 patients achieving a deep molecular response (MR4-4.5). No thrombotic events were recorded. The dose was reduced during treatment in 2 patients due to intolerance and in 8 patients in order to reduce the cardiovascular risk. Ponatinib seems a valid second-line treatment option for chronic phase CML, in particular for patients who failed a front-line second-generation TKI due to BCR-ABL-independent mechanisms of resistance.

Breccia, M., Abruzzese, E., Castagnetti, F., Bonifacio, M., Gangemi, D., Sorà, F., Iurlo, A., Luciano, L., Gozzini, A., Gentile, M., Bocchia, M., Luzi, D., Maggi, A., Sgherza, N., Isidori, A., Crugnola, M., Pregno, P., Scortechini, A., Capodanno, I., Pizzuti, M., Foà, R., Ponatinib as second-line treatment in chronic phase chronic myeloid leukemia patients in real-life practice., <<ANNALS OF HEMATOLOGY>>, 2018; (97): 1577-1580 [http://hdl.handle.net/10807/135713]

Ponatinib as second-line treatment in chronic phase chronic myeloid leukemia patients in real-life practice.

Sorà F;Gentile M;Pizzuti M;Foà R.
2018

Abstract

Scarce information is available on the use of ponatinib as second-line treatment in chronic phase chronic myeloid leukemia (CP-CML) patients resistant and/or intolerant to prior tyrosine kinase inhibitor (TKI) therapy. We collected data from 29 CML patients, with a median age of 54 years (range 32-72). Eleven patients had received dasatinib, 15 patients received nilotinib, and 3 patients received imatinib as first-line treatment. Forty-five percent of patients started ponatinib for secondary resistance, 38% for primary resistance, 7% for severe intolerance associated to a molecular warning, 7% due to the presence of a T315I mutation, and 3% for severe intolerance. Ponatinib was started at a dose of 45 mg in 60% of patients, 30 mg in 38%, and 15 mg in 2% of patients. Overall, at a median follow-up of 12 months, 85% of treated patients improved the level of response as compared to baseline, with 10 patients achieving a deep molecular response (MR4-4.5). No thrombotic events were recorded. The dose was reduced during treatment in 2 patients due to intolerance and in 8 patients in order to reduce the cardiovascular risk. Ponatinib seems a valid second-line treatment option for chronic phase CML, in particular for patients who failed a front-line second-generation TKI due to BCR-ABL-independent mechanisms of resistance.
Inglese
Breccia, M., Abruzzese, E., Castagnetti, F., Bonifacio, M., Gangemi, D., Sorà, F., Iurlo, A., Luciano, L., Gozzini, A., Gentile, M., Bocchia, M., Luzi, D., Maggi, A., Sgherza, N., Isidori, A., Crugnola, M., Pregno, P., Scortechini, A., Capodanno, I., Pizzuti, M., Foà, R., Ponatinib as second-line treatment in chronic phase chronic myeloid leukemia patients in real-life practice., <>, 2018; (97): 1577-1580 [http://hdl.handle.net/10807/135713]
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/10807/135713
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? ND
social impact